SUNRISE, Fla., Dec 18, 2008 — Bioheart, Inc. (Nasdaq:BHRT) and Life Technologies Corporation (Nasdaq:LIFE) have entered into a global distribution and OEM agreement to sell myoblast cell-based research products to life science researchers. Life Technologies will offer Bioheart’s myoblast stem cell products to the research community so that they may accelerate the development of myoblast stem cell applications.

Myoblasts, or muscle derived stem cells, have been utilized in more than 7,000 scientific papers and abstracts in a variety of indications from heart failure to muscular dystrophy. In particular, when injected into scar tissue within the heart wall, myoblasts have been shown to be capable of engrafting in the damaged tissue and differentiating into mature skeletal muscle cells. Myoblasts are the only cell which has demonstrated an ability to generate new muscle tissue within the scarred regions of a heart.

The new myoblast products will complement Life Technologies’ many reagents that are used to isolate, characterize, expand and differentiate stem cells.

“Partnering with Life Technologies, a global biotechnology company, ensures that myoblasts obtained by our proprietary technology will be available to academic and industrial researchers worldwide and is another step toward becoming a commercial company,” said Howard J. Leonhardt, Chairman, CEO and CTO of Bioheart. “This distribution agreement will give us access to the research community and will expand the number of therapeutic applications under development with this type of cell.”